| Date Filed | Type | Description |
| 01/09/2020 |
GN
| IBKC, THOR, TIF, and AMTD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts |
| 01/07/2020 |
GN
| WAAS, TIVO, THOR, and CRCM SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts |
| 01/02/2020 |
GN
| CBB, TGE, INST, and THOR SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts |
| 12/30/2019 |
GN
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – INST, THOR, TCBI, ARQL |
| 12/28/2019 |
GN
| THOR, ARQL, TIF, and AMTD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts |
| 12/21/2019 |
GN
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – BOLD, INST, THOR |
| 12/12/2019 |
GN
| SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Mergers |
| 12/09/2019 |
GN
| Synthorx Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Synthorx, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – THOR |
| 09/23/2019 |
GN
| Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress |
| 09/09/2019 |
GN
| Synthorx to Present at the 2019 World Congress of Inflammation |
| 08/29/2019 |
GN
| Synthorx to Present at H.C. Wainwright 21st Annual Global Investment Conference |
| 07/24/2019 |
GN
| Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707 |
| 05/29/2019 |
GN
| Synthorx to Present at Jefferies 2019 Healthcare Conference |
| 05/15/2019 |
GN
| Synthorx to Present at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting |
| 03/19/2019 |
GN
| Synthorx to Present at the American Association of Cancer Research (AACR) Annual Meeting 2019 |
| 02/21/2019 |
GN
| Synthorx to Present at the 8th Annual SVB Leerink Global Healthcare Conference |
| 12/20/2018 |
GN
| Synthorx Appoints Andrew Powell, J.D., to its Board of Directors |
| 12/12/2018 |
GN
| Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares |
| 12/06/2018 |
GN
| Synthorx Announces Pricing of Initial Public Offering |
| 10/08/2015 |
8-K
| Quarterly results |
| 10/08/2015 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa... |
| 10/01/2015 |
8-K
| Other Events |
| 10/01/2015 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 09/08/2015 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition |
| 08/31/2015 |
8-K
| Other Events |
| 08/31/2015 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 08/21/2015 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 08/05/2015 |
10-Q
| Quarterly Report for the period ended July 4, 2015 |
| 08/05/2015 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 08/04/2015 |
8-K
| Quarterly results |
| 08/03/2015 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 07/24/2015 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 07/24/2015 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 07/23/2015 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|